| For: | Cigrovski Berkovic M, Strollo F. Semaglutide-eye-catching results. World J Diabetes 2023; 14(4): 424-434 [PMID: 37122431 DOI: 10.4239/wjd.v14.i4.424] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v14/i4/424.htm |
| Number | Citing Articles |
| 1 |
Moiz Lakhani, Angela T.H. Kwan, Andrew Mihalache, Marko M. Popovic, Keean Nanji, Jim S. Xie, Alessandro Feo, David Rabinovitch, Reut Shor, SriniVas Sadda, David Sarraf, Bernard Hurley, Edward A. Margolin, Peter J. Kertes, Varun Chaudhary, Rajeev H. Muni. Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries. American Journal of Ophthalmology 2025; 277 doi: 10.1016/j.ajo.2025.05.007
|
| 2 |
Raghav Gupta, Shivani Sharma. Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity. Current Signal Transduction Therapy 2025; 20(2) doi: 10.2174/0115743624346660250317013032
|
| 3 |
Sarita Jacob, George I. Varughese. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. Annals of Pharmacotherapy 2024; 58(4) doi: 10.1177/10600280231224039
|
| 4 |
Bin Wang, Zi-qiang Chen, Cong Hu, Si-Man Wang, Xing-Kai Qian, Li-Wei Zou, Ling Yang. Construction and validation of a method for detecting DPP-IV activity and tissue distribution in C57 mice based on a fluorescent probe. Analytical Methods 2026; 18(3) doi: 10.1039/D5AY01757B
|
| 5 |
Stefania Chiappini, Rachel Vickers-Smith, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi, Fabrizio Schifano. Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals 2023; 16(7) doi: 10.3390/ph16070994
|
| 6 |
George Iype Varughese, Sarita Jacob. Existing and emerging GLP-1 receptor agonist therapy: Ramifications for diabetic retinopathy screening. Journal of the Royal College of Physicians of Edinburgh 2024; 54(2) doi: 10.1177/14782715241244843
|
| 7 |
Yosra Turkistani. Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective. Frontiers in Cardiovascular Medicine 2025; 12 doi: 10.3389/fcvm.2025.1535134
|
| 8 |
Xiao Cheng, Zhuoxin Fu, Yucai Chen, Jiawei Wang, Furong Han. Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro. Diabetes, Obesity and Metabolism 2025; 27(12) doi: 10.1111/dom.70107
|
| 9 |
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides 2025; 187 doi: 10.1016/j.peptides.2025.171380
|
| 10 |
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen. Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy. Acta Ophthalmologica 2026; doi: 10.1111/aos.70168
|
| 11 |
Dimitris Kounatidis, Natalia G. Vallianou, Eleni Rebelos, Kalliopi Vallianou, Evanthia Diakoumopoulou, Konstantinos Makrilakis, Nikolaos Tentolouris. The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?. Biomolecules 2025; 15(9) doi: 10.3390/biom15091284
|
| 12 |
Atia Arif, Sanu Lama, Bhavna Singla, Shivam Singla, Sunita Kumawat, Anusha Tharwani, Muhammad Usman, Hamna Khalid, Venkata Madusudana Rao Kanukollu, Osatohanmwen Ekomwereren, Shabir Khan. Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence. Cureus 2025; doi: 10.7759/cureus.92976
|
| 13 |
Salem Abu Al-Burak, Vitaliy Voznyy, Mouad Elganga, Chris Zajner, Verena Juncal, Thomas G. Sheidow, Monali S. Malvankar-Mehta. Diabetic macular edema and GLP-1 receptor agonist use: a systematic review and meta-analysis. Canadian Journal of Ophthalmology 2026; doi: 10.1016/j.jcjo.2026.05.004
|
| 14 |
Mashael Al-Namaeh. Systemic Medications and Their Ocular Side Effects. Cureus 2024; doi: 10.7759/cureus.74976
|